Basilea Pharmaceutica (BPMUF) News Today → The Best AI Stock to Own in the World Today is Trading for Just $25 (From Banyan Hill Publishing) (Ad) Free BPMUF Stock Alerts $44.45 0.00 (0.00%) (As of 04/25/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartHeadlinesShort InterestStock AnalysisChartHeadlinesShort Interest All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineBasilea shareholders approve all proposals of the board of directors at the annual general meetingfinance.yahoo.com - April 24 at 2:20 PMBasilea Pharmaceutica AG (0QNA.L)finance.yahoo.com - April 24 at 9:20 AMBasilea awarded CARB-X grant to develop recently acquired novel class of antibioticsfinance.yahoo.com - April 9 at 7:12 AMUPDATE 2-US FDA approves Basilea Pharmaceutica's antibioticmsn.com - April 4 at 2:25 PMEuropean stocks rise ahead of inflation data; Basilea shinesmsn.com - April 4 at 7:19 AMBasilea announces US FDA approval of antibiotic ZEVTERA® (ceftobiprole medocaril) for three indicationsfinance.yahoo.com - April 4 at 2:18 AMUS FDA approves Basilea Pharmaceutica's antibioticreuters.com - April 3 at 3:34 PMContinued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basileafinance.yahoo.com - March 11 at 10:26 AMBasilea Pharmaceutica AG Expected to Earn FY2024 Earnings of $1.85 Per Share (OTCMKTS:BPMUF)marketbeat.com - February 22 at 7:50 AMBasilea Pharmaceutica AG (BSLN)investing.com - February 21 at 5:30 PMBasilea reports strong 2023 full-year results with profitability significantly above guidance, whilst substantially expanding the R&D portfoliofinance.yahoo.com - February 13 at 3:21 AMCresemba® sales in Latin America trigger first sales milestone payment to Basileafinance.yahoo.com - January 19 at 4:53 AMBasilea To Buy Preclinical Antibiotics Program From Spexismarkets.businessinsider.com - January 15 at 7:49 AMBasilea announces acquisition of preclinical antibiotics program from Spexisfinance.yahoo.com - January 15 at 7:49 AMBasilea provides portfolio status updatefinance.yahoo.com - January 5 at 1:57 AMBasilea Pharmaceutica Agrees With Athyrium On Early Repayment Of Senior Secured Loanmarkets.businessinsider.com - December 20 at 8:44 AMBasilea announces accelerated loan repaymentfinance.yahoo.com - December 20 at 8:44 AMBasilea announces that FDA approves expanded use of antifungal Cresemba® (isavuconazole) in the United States in children with invasive aspergillosis and invasive mucormycosisfinance.yahoo.com - December 11 at 5:58 AMBasilea Pharmaceutica AG's (VTX:BSLN) top owners are individual investors with 58% stake, while 39% is held by institutionsfinance.yahoo.com - December 4 at 7:50 AMContinued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers third sales milestone payment for the region from Pfizer this yearfinance.yahoo.com - November 20 at 8:47 AMPfizer unit in pact with Swiss biotech Basilea to sell rights to antifungalmsn.com - November 13 at 5:49 PMBasilea announces acquisition of fosmanogepix, a phase-3-ready broad-spectrum antifungalfinance.yahoo.com - November 13 at 7:49 AMBasilea announces exclusive license and option agreement for potential first-in-class clinical-stage antibacterial agentfinance.yahoo.com - October 31 at 8:16 AMBasilea announces acquisition of novel clinical-stage antifungal for treatment of Aspergillus mold infectionsfinance.yahoo.com - October 19 at 9:16 AMBasilea reports new data for ceftobiprole (Zevtera®) presented at US IDWeek Congress 2023finance.yahoo.com - October 17 at 9:33 AMBasilea announces FDA acceptance of New Drug Application for antibiotic ceftobiprolefinance.yahoo.com - October 2 at 5:05 AMBasilea announces New England Journal of Medicine publication of phase 3 data on ceftobiprole for the treatment of Staphylococcus aureus bacteremiafinance.yahoo.com - September 28 at 8:12 AMBasilea reports strong revenue and profit growth in first half-year 2023finance.yahoo.com - August 15 at 1:54 AMBasilea Pharma Submits NDA For Antibiotic Ceftobiprolemarkets.businessinsider.com - August 4 at 5:23 AMBasilea announces submission of a New Drug Application to the US Food and Drug Administration for its antibiotic ceftobiprolefinance.yahoo.com - August 4 at 5:23 AMContinued strong Cresemba® (isavuconazole) sales by Pfizer trigger USD 26 million sales milestone payments to Basileafinance.yahoo.com - June 8 at 3:34 AMBasilea provides update on New Drug Application to the US Food and Drug Administration for antibiotic ceftobiprolefinance.yahoo.com - April 18 at 3:33 AMBasilea Pharmaceutica Posts FY Profitmarkets.businessinsider.com - February 14 at 7:57 AMBasilea reports strong financial results 2022 based on successful implementation of new strategyfinance.yahoo.com - February 14 at 1:55 AMContinued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers second sales milestone payment to Basilea from Pfizerfinance.yahoo.com - February 7 at 2:46 AMBasilea Pharma Expects Net Profit In FY22markets.businessinsider.com - January 24 at 4:14 AMBasilea reports preliminary operating profit for 2022, significantly above guidancefinance.yahoo.com - January 24 at 4:14 AMBasilea reports preliminary 2022 revenues, exceeding guidance, and provides portfolio updatefinance.yahoo.com - January 11 at 8:33 AMContinued strong Cresemba® (isavuconazole) sales by Astellas in the U.S. trigger CHF 20 million sales milestone payment to Basileafinance.yahoo.com - January 9 at 10:05 AMBasilea announces repayment of 2022 convertible bondsfinance.yahoo.com - December 28 at 4:33 AMBasilea announces regulatory approval of antifungal Cresemba® (isavuconazole) in Japanfinance.yahoo.com - December 23 at 9:49 AMBasilea announces transition milestone for oncology asset BAL0891, triggering milestone payment of USD 4 million by SillaJenfinance.yahoo.com - December 19 at 8:32 AMHere's Why Momentum in Basilea Pharmaceutica AG (BPMUF) Should Keep goingfinance.yahoo.com - December 14 at 12:29 PMIs Basilea Pharmaceutica (BPMUF) Outperforming Other Medical Stocks This Year?finance.yahoo.com - December 9 at 12:56 PMHere's What Could Help Basilea Pharmaceutica AG (BPMUF) Maintain Its Recent Price Strengthfinance.yahoo.com - November 28 at 5:47 PMBasilea Pharma To Sell Preclinical CLK Kinase Inhibitors To Twentyeight-SevenTherapeuticsnasdaq.com - November 2 at 6:09 AMBasilea announces sale of preclinical oncology program to Twentyeight-Seven Therapeuticsfinance.yahoo.com - November 2 at 6:09 AMBasilea announces late breaking presentation on the successfully completed ERADICATE phase 3 study with ceftobiprole in Staphylococcus aureus bacteremia (SAB) at IDWeek 2022finance.yahoo.com - October 13 at 1:18 AMBasilea Pharmaceutica AGreuters.com - October 8 at 12:52 PMBasilea announces closing of CHF 75 million senior secured loan agreement with Athyriumfinance.yahoo.com - September 21 at 4:58 AM Get Basilea Pharmaceutica News Delivered to You Automatically Sign up to receive the latest news and ratings for BPMUF and its competitors with MarketBeat's FREE daily newsletter. Email Address A new way to collect income from stocks (Ad)Most people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… Click here to see me place one of these trades LIVE on camera. BPMUF Media Mentions By Week BPMUF Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BPMUF News Sentiment▼0.650.41▲Average Medical News Sentiment BPMUF News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BPMUF Articles This Week▼30▲BPMUF Articles Average Week Get Basilea Pharmaceutica News Delivered to You Automatically Sign up to receive the latest news and ratings for BPMUF and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: AVBP News Today ATXS News Today PHAT News Today STOK News Today ALT News Today ANAB News Today CMPS News Today KRRO News Today CALT News Today PAHC News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:BPMUF) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersFed launches fourth dollar overhaulStansberry ResearchThe AI stock to buy right nowStockEarningsExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersKeep Your Eyes on This Power-Mad PoliticianAltimetryThe Next Nvidia?InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Basilea Pharmaceutica AG Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
